Related references
Note: Only part of the references are listed.Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3-or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
Josep M. Llibre et al.
CLINICAL INFECTIOUS DISEASES (2023)
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
Carmen Hidalgo-Tenorio et al.
VIRUSES-BASEL (2022)
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV
Charlotte-Paige Rolle et al.
AIDS (2021)
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
Jean van Wyk et al.
CLINICAL INFECTIOUS DISEASES (2020)
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Pedro Cahn et al.
LANCET (2019)
A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results
Tessa Kennedy-Martin et al.
TRIALS (2015)
The cohort of the spanish hiv research network (coris) and its associated biobank; organizational issues, main findings and losses to follow-up
Paz Sobrino-Vegas et al.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2011)
Share Paper
